Logo image of MASI

MASIMO CORP (MASI) Stock Fundamental Analysis

NASDAQ:MASI - Nasdaq - US5747951003 - Common Stock - Currency: USD

146.28  -0.48 (-0.33%)

Fundamental Rating

4

Overall MASI gets a fundamental rating of 4 out of 10. We evaluated MASI against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of MASI get a neutral evaluation. Nothing too spectacular is happening here. MASI has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

MASI had positive earnings in the past year.
In the past year MASI had a positive cash flow from operations.
Of the past 5 years MASI 4 years were profitable.
Each year in the past 5 years MASI had a positive operating cash flow.
MASI Yearly Net Income VS EBIT VS OCF VS FCFMASI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

MASI has a Return On Assets (-19.11%) which is in line with its industry peers.
MASI has a Return On Equity of -44.04%. This is comparable to the rest of the industry: MASI outperforms 51.87% of its industry peers.
MASI's Return On Invested Capital of 5.19% is fine compared to the rest of the industry. MASI outperforms 78.61% of its industry peers.
MASI had an Average Return On Invested Capital over the past 3 years of 4.58%. This is below the industry average of 8.08%.
The 3 year average ROIC (4.58%) for MASI is below the current ROIC(5.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -19.11%
ROE -44.04%
ROIC 5.19%
ROA(3y)-1.49%
ROA(5y)4.35%
ROE(3y)-4.1%
ROE(5y)3.92%
ROIC(3y)4.58%
ROIC(5y)8.17%
MASI Yearly ROA, ROE, ROICMASI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

MASI has a better Operating Margin (6.43%) than 72.19% of its industry peers.
In the last couple of years the Operating Margin of MASI has declined.
Looking at the Gross Margin, with a value of 52.76%, MASI is in line with its industry, outperforming 45.99% of the companies in the same industry.
MASI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.43%
PM (TTM) N/A
GM 52.76%
OM growth 3Y-55.93%
OM growth 5Y-39.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.74%
GM growth 5Y-6.5%
MASI Yearly Profit, Operating, Gross MarginsMASI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so MASI is destroying value.
Compared to 1 year ago, MASI has more shares outstanding
MASI has about the same amout of shares outstanding than it did 5 years ago.
MASI has a better debt/assets ratio than last year.
MASI Yearly Shares OutstandingMASI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
MASI Yearly Total Debt VS Total AssetsMASI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 5.58 indicates that MASI is not in any danger for bankruptcy at the moment.
MASI has a better Altman-Z score (5.58) than 83.42% of its industry peers.
MASI has a debt to FCF ratio of 4.14. This is a neutral value as MASI would need 4.14 years to pay back of all of its debts.
MASI's Debt to FCF ratio of 4.14 is amongst the best of the industry. MASI outperforms 83.42% of its industry peers.
A Debt/Equity ratio of 0.57 indicates that MASI is somewhat dependend on debt financing.
MASI's Debt to Equity ratio of 0.57 is on the low side compared to the rest of the industry. MASI is outperformed by 67.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 4.14
Altman-Z 5.58
ROIC/WACC0.61
WACC8.48%
MASI Yearly LT Debt VS Equity VS FCFMASI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 2.14 indicates that MASI has no problem at all paying its short term obligations.
MASI has a Current ratio of 2.14. This is in the lower half of the industry: MASI underperforms 60.96% of its industry peers.
MASI has a Quick Ratio of 1.61. This is a normal value and indicates that MASI is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of MASI (1.61) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 1.61
MASI Yearly Current Assets VS Current LiabilitesMASI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.84% over the past year.
The Earnings Per Share has been growing slightly by 5.86% on average over the past years.
The Revenue has decreased by -8.36% in the past year.
The Revenue has been growing by 17.43% on average over the past years. This is quite good.
EPS 1Y (TTM)60.84%
EPS 3Y2.37%
EPS 5Y5.86%
EPS Q2Q%54.65%
Revenue 1Y (TTM)-8.36%
Revenue growth 3Y19.12%
Revenue growth 5Y17.43%
Sales Q2Q%-25.27%

3.2 Future

Based on estimates for the next years, MASI will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.14% on average per year.
MASI is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.12% yearly.
EPS Next Y18.58%
EPS Next 2Y13.54%
EPS Next 3Y14.5%
EPS Next 5Y12.14%
Revenue Next Year-27.16%
Revenue Next 2Y-11.41%
Revenue Next 3Y-5.32%
Revenue Next 5Y-0.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MASI Yearly Revenue VS EstimatesMASI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
MASI Yearly EPS VS EstimatesMASI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 27.39, MASI can be considered very expensive at the moment.
75.40% of the companies in the same industry are more expensive than MASI, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.85, MASI is valued at the same level.
Based on the Price/Forward Earnings ratio of 26.51, the valuation of MASI can be described as expensive.
Based on the Price/Forward Earnings ratio, MASI is valued a bit cheaper than 73.80% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.98. MASI is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 27.39
Fwd PE 26.51
MASI Price Earnings VS Forward Price EarningsMASI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

MASI's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. MASI is cheaper than 66.84% of the companies in the same industry.
MASI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. MASI is cheaper than 74.87% of the companies in the same industry.
Industry RankSector Rank
P/FCF 53.45
EV/EBITDA 44.16
MASI Per share dataMASI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
MASI's earnings are expected to grow with 14.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.47
PEG (5Y)4.68
EPS Next 2Y13.54%
EPS Next 3Y14.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MASI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MASIMO CORP

NASDAQ:MASI (8/20/2025, 3:27:23 PM)

146.28

-0.48 (-0.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-03 2025-11-03/amc
Inst Owners102.04%
Inst Owner Change5.62%
Ins Owners0.17%
Ins Owner Change3.1%
Market Cap7.93B
Analysts82.67
Price Target187.42 (28.12%)
Short Float %6.55%
Short Ratio4.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.44%
Min EPS beat(2)6.64%
Max EPS beat(2)10.25%
EPS beat(4)4
Avg EPS beat(4)11.67%
Min EPS beat(4)6.64%
Max EPS beat(4)14.9%
EPS beat(8)8
Avg EPS beat(8)11.28%
EPS beat(12)12
Avg EPS beat(12)9.75%
EPS beat(16)16
Avg EPS beat(16)8.76%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.35%
Max Revenue beat(2)-0.77%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.58%
Max Revenue beat(4)-0.59%
Revenue beat(8)0
Avg Revenue beat(8)-1.74%
Revenue beat(12)2
Avg Revenue beat(12)-1.66%
Revenue beat(16)5
Avg Revenue beat(16)-1.07%
PT rev (1m)0.92%
PT rev (3m)-6.11%
EPS NQ rev (1m)5.64%
EPS NQ rev (3m)-2.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.42%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-6.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 27.39
Fwd PE 26.51
P/S 4.29
P/FCF 53.45
P/OCF 44.91
P/B 7.61
P/tB 8.97
EV/EBITDA 44.16
EPS(TTM)5.34
EY3.65%
EPS(NY)5.52
Fwd EY3.77%
FCF(TTM)2.74
FCFY1.87%
OCF(TTM)3.26
OCFY2.23%
SpS34.09
BVpS19.23
TBVpS16.31
PEG (NY)1.47
PEG (5Y)4.68
Profitability
Industry RankSector Rank
ROA -19.11%
ROE -44.04%
ROCE 6.57%
ROIC 5.19%
ROICexc 5.66%
ROICexgc 6.25%
OM 6.43%
PM (TTM) N/A
GM 52.76%
FCFM 8.03%
ROA(3y)-1.49%
ROA(5y)4.35%
ROE(3y)-4.1%
ROE(5y)3.92%
ROIC(3y)4.58%
ROIC(5y)8.17%
ROICexc(3y)4.95%
ROICexc(5y)12.77%
ROICexgc(3y)9.27%
ROICexgc(5y)17.89%
ROCE(3y)5.8%
ROCE(5y)10.34%
ROICexcg growth 3Y-55.81%
ROICexcg growth 5Y-40.49%
ROICexc growth 3Y-58.97%
ROICexc growth 5Y-44.46%
OM growth 3Y-55.93%
OM growth 5Y-39.54%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.74%
GM growth 5Y-6.5%
F-Score6
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 0.57
Debt/FCF 4.14
Debt/EBITDA 3.14
Cap/Depr 39.28%
Cap/Sales 1.53%
Interest Coverage 3.59
Cash Conversion 92.61%
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 1.61
Altman-Z 5.58
F-Score6
WACC8.48%
ROIC/WACC0.61
Cap/Depr(3y)60.07%
Cap/Depr(5y)110.25%
Cap/Sales(3y)3.16%
Cap/Sales(5y)3.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.84%
EPS 3Y2.37%
EPS 5Y5.86%
EPS Q2Q%54.65%
EPS Next Y18.58%
EPS Next 2Y13.54%
EPS Next 3Y14.5%
EPS Next 5Y12.14%
Revenue 1Y (TTM)-8.36%
Revenue growth 3Y19.12%
Revenue growth 5Y17.43%
Sales Q2Q%-25.27%
Revenue Next Year-27.16%
Revenue Next 2Y-11.41%
Revenue Next 3Y-5.32%
Revenue Next 5Y-0.12%
EBIT growth 1Y-27.14%
EBIT growth 3Y-47.5%
EBIT growth 5Y-29%
EBIT Next Year44.59%
EBIT Next 3Y17.5%
EBIT Next 5Y13.83%
FCF growth 1Y624.38%
FCF growth 3Y-14.18%
FCF growth 5Y-0.52%
OCF growth 1Y535.25%
OCF growth 3Y-9.48%
OCF growth 5Y-2.39%